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ABSTRACT
Acne vulgaris is very common among adolescents and young adults. Permanent scarring, poor self-image, 
depression, and anxiety can result from it. The acne treatment options include topical therapies, systemic 
agents, physical modalities, lasers, photodynamic therapy or combinations. Oral isotretinoin is widely 
recognised as a very effective treatment for severe acne. However, it may cause adverse effects. 
We report a case of an 18-year-old man affected by thalassemia minor treated with oral isotretinoin because 
of a severe form of acne unresponsive to conventional oral antibiotic therapy. During the treatment clinical 
and biochemical evaluations were closely monitored each month in order to discover potential adverse 
effects of isotretinoin and the impact over thalassemia. After 9 months of oral isotretinoin application we 
can tell that the drug was well tolerated by the patient, the acne totally cleared, and the thalassemia did not 
deteriorate. 
In conclusion, although a highly effective drug, isotretinoin use is limited by its side effects. However, 
patients may accept these procedures to improve the psychosocial effects of acne, because it can target all 
aspects of acne pathology. Something else, it is the choice of treatment in antibiotic-resistant forms of acne. 
It has been seen that the oral isotretinoin could be successfully used in patients with severe acne suffering 
from thalassemia minor in which the antibiotic treatment failed with the explicit requirement for strict 
clinical and biochemical follow-up.
Keywords: acne vulgaris, oral isotretinoin, thalassemia minor
Address for correspondence:  
Vessela Raykova
Medical University - Sofia
15 Akad. Ivan Geshov Blvd
1431 Sofia
e-mail: pumpi@abv.bg
Received: May 25, 2020
Accepted: June 9, 2020
INTRODUCTION
Acne vulgaris (AV), a chronic inflammato-
ry disease of the pilosebaceous unit, is a common-
ly diagnosed inflammatory skin condition that af-
fects more than 80% of teenagers but also adults. Al-
though acne is not physically disabling, its psycho-
logical impact can be striking, contributing to low 
self-esteem, depression, anxiety and lower quality of 
life (1-3). As a result, there is a significant need for ef-
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The drug isotretinoin (13‐cis‐retinoic acid) is 
derived from vitamin A. It is available for topical and 
oral administration. Oral isotretinoin was approved 
by the US Food and Drug Administration for nodu-
locystic acne in 1982 and introduced into the United 
Kingdom in 1983 (6). Since then, it has revolution-
ised the treatment of acne and, three decades later, 
remains the most clinically effective anti‐acne ther-
apy according to physicians’ opinion (7). It is effec-
tive in resolving acne and improving quality of life 
(8) and is better in reducing lesions than other agents 
such as oral antibiotics and topical combinations (9). 
Isotretinoin is used as  0.5 mg/kg to 1 mg/kg body 
weight in daily or weekly pulse regimen. It controls 
sebum production, regulates pilosebaceous epider-
mal hyperproliferation, and  reduces inflammation 
by controlling C. acnes.
Although a highly effective drug, oral isotreti-
noin use is limited by its many and diverse side ef-
fects. Some of them are dry mucous membranes, 
muscle pain, and headaches. The teratogenic effects 
are many, including, but not limited to, spontane-
ous abortions and abnormalities of the face, cardio-
vascular system, and parathyroid glands. Serum tri-
glycerides and liver enzymes may increase with use. 
In addition, blood dyscrasias may occur. Controver-
sial evidence regarding the rare adverse events relat-
ed to isotretinoin such as inflammatory bowel dis-
ease (IBD), suicidal ideation, and suicide. 
CASE PRESENTATION
We report a case of an 18-year-old person af-
fected by thalassemia minor diagnosed in early 
childhood and treated with oral isotretinoin because 
of a severe form of acne unresponsive to convention-
al oral antibiotic therapy. Doxycycline therapy was 
the first choice given orally at a daily dose of 100 mg 
for 3 months associated with topical benzoyl perox-
ide and adapalene. The decision to start with an an-
tibiotic and not with isotretinoin was based on the 
presence of thalassemia minor that has the potential 
to affect the liver and bones. 
Thalassemia is an inherited blood disorder in 
which the body makes an abnormal form of hemo-
globin. The disorder results in excessive destruction 
of red blood cells, which leads to anemia and symp-
toms as bone deformities (especially in the face), dark 
fective therapy. The acne treatment options include 
topical therapies, systemic agents, physical modali-
ties, lasers, photodynamic therapy or their combina-
tions. Oral isotretinoin is widely recognised as a very 
effective treatment for severe acne but with many ad-
verse effects.
A patient with thalassemia minor and with 
antibiotic-resistant acne vulgaris treated with oral 
isotretinoin is the focus of this case report. The in-
dividual’s acne lesions found over the face, chest and 
back were presented by erythematous and pigment-
ed macules, papules, pustules, nodules, pseudocysts, 
cysts, and scars. 
DISCUSSION
Acne vulgaris is an inflammatory disorder of 
the pilosebaceous unit, which runs a chronic course. 
Acne vulgaris is triggered by Cutibacterium acnes in 
adolescence, under the influence of normal circu-
lating dehydroepiandrosterone. It is a very common 
skin disorder, which can present with inflammatory 
and non-inflammatory lesions chiefly on the face but 
can also occur on the upper arms, trunk, and back. 
Although acne is not physically disabling, its 
psychological impact can be striking. Adolescent 
patients have reported low self-esteem, symptoms 
of depression and anxiety, and lower quality of life. 
As a result, there is a significant need for effective 
therapy. The acne treatment options include topical 
therapies, systemic agents, physical modalities, 
lasers, photodynamic therapy or their combinations. 
Acne medications work by reducing oil production, 
speeding up skin cell turnover, fighting bacterial 
infection or reducing inflammation — which helps 
prevent scarring. They depend on the age, the type 
and severity of the acne, as well as the possibility of 
scarring. An interesting fact is that the therapeutic 
activities for acne have changed little in the last 
decade (4). Recognition that acne is an inflammatory 
condition, not an infectious one, has led to a call for 
reduction in antibiotic use, which has culminated in 
a re-evaluation of nonantibiotic choices. There are 
a number of effective agents for topical treatment 
of mild to moderate acne. Spironolactone and oral 
contraceptives have become more acceptable first-
line choices, and earlier use of isotretinoin has been 
proposed (4), especially in cases of severe, therapy-
resistant acne (5).
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urine, delayed growth and development, excessive 
tiredness and fatigue, and yellow or pale skin. 
The response to the applied antibiotic treat-
ment was not good, and the patient presented with 
an increased psychological acne-related distur-
bance (APSEA score value of 115/139; score signifi-
cance: very high). Then treatment with oral isotret-
inoin was discussed and started after careful eval-
uation of all the positives and negatives. Our deci-
sion for this treatment was based on the guidelines of 
the American Academy of Dermatology (AAD) that 
states that isotretinoin is effective in severe nodular 
acne or other stages of disease severity where first-
line treatments have failed. Something else the Eu-
roGuiDerm Guidelines give the highest recommen-
dation to using oral isotretinoin in both severe papu-
lopustular/moderate nodular acne and severe nodu-
lar/conglobate acne. Another argument in favor was 
the literature data that showed that there is accumu-
lated experience with oral isotretinoin treatment in 
patients even with thalassemia major with excellent 
results (10). 
The pretreatment laboratory screening of our 
patient was needed (11) and it showed no devia-
tions. Isotretinoin was given for one month at an ini-
tial dosage of 0.5mg/kg/day in two divided doses to 
minimize the risk of adverse events. Then after new 
biochemical evaluation and results within the refer-
ence limits the dose was increased to 1 mg/kg/day for 
some weeks (10-12) until good response to the treat-
ment was seen. Afterwards very slow discontinua-
tion of the medication was done for some months.  
Taken with food, the typical dosage of oral 
isotretinoin is 0.5–1 mg/kg/day for about 20 weeks or 
a cumulative dose of 120 mg/kg (13). An initial dos-
age of 0.5 mg/kg/day given in two divided doses may 
minimize the risk of adverse events. The suggested 
cumulative dose over 20 weeks should be 120–150 
mg because smaller or larger dosages can increase 
the risk of relapse and adverse effects, respectively. 
For severe papulopustular acne, the EDF guidelines 
recommend 0.3–0.5 mg/kg/day continued for at least 
6 months; this recommendation is based on expert 
opinion rather than on available evidence, which was 
Fig. 1. During the therapy Fig. 2. During the therapy
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deemed conflicting and limited in determining the 
best dosage (14). Lower doses (0.1–0.2 mg/kg/day) 
might lessen the incidence of adverse effects, but the 
duration of use would be prolonged.
In our patient, during all the treatment period 
each month, clinical, biochemical (lipid panel, liver 
function tests, blood cell count, ferritin concentra-
tion, coagulation assessment, calcium and parathy-
roid serum levels) and bone densitometry evaluations 
were closely monitored in order to discover possible 
adverse effects of isotretinoin potentially causing im-
balance in the patient’s basic health and because of 
its primary condition – the presence of thalassemia 
minor that could be aggravated by the applied ther-
apy.  And overall, the drug was well tolerated. Our 
patient showed no liver and bone disturbances from 
the very beginning of our treatment until its end. The 
skin status changed dramatically with disappearance 
of the different inflammation lesions. Only the scars 
remained as a witness to the past clinical condition.
CONCLUSION
Although a highly effective drug, isotretinoin 
use is limited by its side effects. However, patients 
may accept these procedures to improve the psycho-
social effects of acne, because it can target all aspects 
of acne pathology. Something else, it is the choice of 
treatment in antibiotic-resistant forms of acne. It has 
been seen that oral isotretinoin could be successful-
ly used in patients with severe acne suffering from 
thalassemia minor in whom the antibiotic treatment 
failed with the explicit requirement for strict clinical 
and biochemical follow-up.
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